BCG immunization and COVID-19 disease association

Main Article Content

Öner Özdemir

Keywords

COVID-19, BCG

Abstract

N/A

Abstract 555 | PDF Downloads 478 HTML Downloads 104 XML Downloads 14

References

1. Sharma AR, Batra G, Kumar M, Mishra A, Singla R, Singh A, Sharma B. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic? Allergol Immunopathol (Madr). 2020 Jul 3;58(5):S0301-0546(20)30106-3. 10.1016/j.aller.2020.05.002.

2. de Bree LCJ, Marijnissen RJ, Kel JM, Rosendahl Huber SK, Aaby P, Benn CS, et al. Bacillus Calmette-Guérin-induced trained immunity is not protective for experimental Influenza A/Anhui/1/2013 (H7N9) infection in mice. Front Immunol. 2018;9:869. 10.3389/fimmu.2018.02471; 10.3390/su10103389

3. Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults [published online ahead of print, 2020 May 13]. JAMA. 2020;323(22):2340–1. 10.1001/jama.2020.8189

4. Meena J, Yadav A, Kumar J. BCG vaccination policy and protection against COVID-19. Indian J Pediatr. 2020;87:749. 10.1007/Fs12098-020-03371-3.

5. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003; 4:9. 10.1186/1471-2350-4-9

6. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. Version 2. J Innate Immun. 2014;6(2):152–8. 10.1159/000355628